{"id":589183,"date":"2022-03-02T15:16:02","date_gmt":"2022-03-02T15:16:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=589183"},"modified":"2022-03-02T15:16:02","modified_gmt":"2022-03-02T15:16:02","slug":"chronic-hand-eczema-market-to-register-incremental-growth-during-the-forecast-period-2032-delveinsight-key-companies-leo-pharma-japan-tobacco-asana-biosciences-basilea-pharma-and-stiefel","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-hand-eczema-market-to-register-incremental-growth-during-the-forecast-period-2032-delveinsight-key-companies-leo-pharma-japan-tobacco-asana-biosciences-basilea-pharma-and-stiefel_589183.html","title":{"rendered":"Chronic Hand Eczema Market to Register Incremental Growth During the Forecast Period 2032 – DelveInsight | Key Companies – LEO Pharma, Japan Tobacco, Asana Biosciences, Basilea Pharma, and Stiefel"},"content":{"rendered":"
\n
\"Chronic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Chronic Hand Eczema Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Chronic Hand Eczema Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n

The Chronic Hand Eczema market<\/strong> report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Chronic<\/p>\n

Chronic Hand Eczema: An Overview<\/strong><\/p>\n

Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belong to the most common skin disorder affecting the hands. It is not a uniform or homogeneous disease and varies by differences in etiology, morphology, and severity. In a substantial number of patients, HE can develop into a chronic condition, which remains active even after avoidance of contact with potentially damaging allergens and\/or irritants.<\/em><\/p>\n

Chronic Hand Eczema (CHE) has been defined as either a long-lasting, relapsing course of HE or HE unresponsive to standard treatment with emollients and topical corticosteroids for more than 3 months or the recurrence of symptoms two or more times within a year despite treatment.<\/em><\/p>\n

As per the National Eczema Association, Hand Eczema\/Hand Dermatitis is a very common condition affecting up to 10% of the population.<\/em><\/p>\n

Chronic Hand Eczema Market Key Facts<\/strong><\/p>\n